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Clozapine is an efficacious atypical antipsychotic for treatment-refractory schizophrenia.
Clinical response and appearance of adverse events vary among individual patients
receiving clozapine, with genetic and non-genetic factors potentially contributing
to individual variabilities. Pharmacogenetic studies investigate associations between
genetic variants and drug efficacy and toxicity. To date, most pharmacogenetic studies
of clozapine have been conducted through candidate gene approaches. A recent
advance in technology made it possible to perform comprehensive genetic mapping
underlying clinical phenotypes and outcomes, which allow novel findings beyond
biological hypotheses based on current knowledge. In this paper, we will summarize the
studies on clozapine pharmacogenetics that have extensively examined clinical response
and agranulocytosis. While there is still limited evidence on clozapine efficacy, recent
genome-wide studies provide further evidence of the involvement of the human leukocyte
antigen (HLA) region in clozapine-induced agranulocytosis.
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INTRODUCTION
Approximately 30% of patients with schizophrenia are treatment-resistant (Meltzer, 1997). Clinical
practice guidelines recommend clozapine in treatment-refractory schizophrenia (Warnez and
Alessi-Severini, 2014), given that it has been shown to be superior for those resistant to treatment
(Siskind et al., 2016). Clozapine may cause serious adverse events, such as agranulocytosis,
cardiomyopathy, and myocarditis (Alvir et al., 1993; De Berardis et al., 2012; Alawami et al., 2014),
so careful monitoring is needed during clozapine treatment. Clinical response and the presence of
adverse events vary among individuals taking clozapine. Although the molecular mechanisms of
clozapine action are still unclear (Yamamori et al., 2013, 2014; Hung et al., 2017; Kinoshita et al.,
2017; Lee et al., 2017; Nakazawa et al., 2017), twin studies suggest that genetic factorsmay contribute
to the variance in therapeutic and adverse effects of clozapine (Vojvoda et al., 1996; Horácek et al.,
2001; Theisen et al., 2001; Wehmeier et al., 2005; Anil Yagcioglu et al., 2011).
Pharmacogenetic studies investigate the associations between genetic variants and drug
efficacy and toxicity (Jorgensen and Williamson, 2008). To date, a number of pharmacogenetic
studies of clozapine have been reported. In this paper, we summarize the studies on clozapine
pharmacogenetics that have extensively examined clinical response and agranulocytosis.
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Clinical Response to Clozapine
Response rate for clozapine ranges from 32% in the short
term to 39% in the long term among those with treatment-
resistant schizophrenia (Siskind et al., 2017). Pharmacogenetic
studies of clinical response to clozapine have focused on
variations in the genes involved in the metabolism of clozapine
[pharmacokinetics, e.g., the cytochrome P 450 (CYP) enzyme
family] and the affinities of clozapine (pharmacodynamics, e.g.,
dopaminergic and serotonergic receptors). Positive candidate
gene studies of the clinical response to clozapine are shown in
Table 1.
Candidate Gene Approach
CYP enzyme related genes
Clozapine is metabolized primarily by CYP1A2, with additional
contributions from CYP2C19, CYP2D6, and CYP3A4 (Urichuk
et al., 2008). To date, genetic variants in the CYP1A2, CYP2C19,
CYP2D6, and CYP3A4 genes as well as in the CYP3A5, CYP3A7,
CYP3A43, and ATP binding cassette subfamily B member 1
(ABCB1) genes have been investigated in clozapine response
studies (Arranz et al., 1995b; Eap et al., 2004; Balibey et al., 2011;
Lee et al., 2012; Rajkumar et al., 2013b; de Brito et al., 2015;
Piatkov et al., 2017). Five studies found significant associations
between the clozapine treatment response and genetic variants
in the CYP1A2, CYP2C19, and ABCB1 genes (Eap et al., 2004;
Balibey et al., 2011; Lee et al., 2012; de Brito et al., 2015;
Piatkov et al., 2017). Eap and colleagues suggested that the
CYP1A2∗1F/∗1F genotype may be associated with low plasma
levels of clozapine and a lack of response to clozapine (N = 4)
(Eap et al., 2004). Balibey and colleagues demonstrated that a
positive response rate of clozapine was significantly lower in
patients carrying the CYP1A2∗1F/∗1F genotype compared to
those with at least one wild type allele for CYP1A2 (N = 97)
(Balibey et al., 2011). De Brite and colleagues replicated these
findings (N = 54) (de Brito et al., 2015). Piatkov and colleagues
demonstrated that homozygote CYP2C19∗17 carriers were five
times more likely to exhibit improvement on clozapine treatment
(N = 45) (Piatkov et al., 2017). Furthermore, Lee and colleagues
demonstrated that rs7787082G and rs10248420A alleles in the
ABCB1 gene were more common in non-responders (N = 96)
(Lee et al., 2012).
Dopamine related genes
Clozapine exhibits a relatively high affinity for the dopamine D4
receptor (DRD4) and relatively lower affinities for the dopamine
D1 receptor (DRD1), the dopamine D2 receptor (DRD2), and the
dopamineD3 receptor (DRD3) (Meltzer, 1994). The combination
of relatively high D1, low D2, and very high 5-HT2 receptor
occupancy rates is unique to clozapine (Mauri et al., 2014). To
date, genetic variants in the DRD1, DRD2, DRD3, DRD4, and
dopamine D5 receptor (DRD5) genes as well as in dopamine -
related genes, Catechol-O-methyltransferase (COMT) and solute
carrier family 6 member 3 (SLC6A3) have been investigated in
clozapine response studies, with positive associations observed in
the DRD1, DRD2, DRD3, DRD4, COMT, and SLC6A3 genes.
With respect to the DRD1 gene (Potkin et al., 2003; Hwang
et al., 2007; Lee et al., 2012), two studies found significant
associations between genetic variants and the clozapine response
(Potkin et al., 2003; Hwang et al., 2007). Potkin and colleagues
demonstrated that rs4532 2/2 carriers were more likely to have
a positive clozapine response following 5 weeks of treatment,
while rs4532 1/2 carriers demonstrated a diminished clozapine
response (N = 15) (Potkin et al., 2003). Hwang and colleagues
demonstrated that rs265976 AC carriers were more likely
to be non-responders to clozapine with a minimum of 6
months treatment in an African American sample (N = 49).
They also investigated an association between three-marker
haplotype (rs265981, rs4532, and rs686) and clozapine response,
demonstrating that the T-G-A haplotype was associated with
poor response in a Caucasian sample (N = 183), while the T-G-
G haplotype was associated with better response in an African
American sample (N = 49) (Hwang et al., 2007). With respect
to the DRD2 gene (Arranz et al., 1998a; Malhotra et al., 1999;
Hwang et al., 2005, 2006; Lee et al., 2012), three studies found
significant associations between genetic variants in this gene
and the clozapine response (Malhotra et al., 1999; Hwang et al.,
2005, 2006). Malhotra and colleagues investigated an association
between 141C Ins/Del (rs1799732) and clozapine response in a
10 week treatment, demonstrating that Del- subjects had a five-
fold greater reduction in psychotic symptoms as compared to
Del+ subjects (N = 72) (Malhotra et al., 1999). Additionally,
Hwang and colleagues investigated an association between 12
single nucleotide polymorphisms (SNPs) in the DRD2 gene
and clozapine response for a minimum of 6 months treatment,
identifying 3 SNPs (Taq1A, Taq1B, and rs1125394) only in
an African-American sample (N = 49) and several haplotypes
in both Caucasian (N = 183) and African-American samples
(N = 49) as being predictive of a clozapine response (Hwang
et al., 2005). This same group later investigated the effect of
the same 12 SNPs in the DRD2 gene on clozapine response
evaluated by overall, positive, and negative symptoms in smaller
sample set (N = 35) and demonstrated that 2 SNPs (Taq1B and
rs1125394) were associated with overall and positive symptom
response to clozapine in an African-American sample (Hwang
et al., 2006). However, a recent meta-analysis (total N = 596)
suggests no association between 141C Ins/Del and a clozapine
treatment response (Gressier et al., 2016). With respect to the
DRD3 gene (Gaitonde et al., 1996; Shaikh et al., 1996; Malhotra
et al., 1998; Scharfetter et al., 1999; Arranz et al., 2000b; Barlas
et al., 2009; Hwang et al., 2010; Lee et al., 2012), three studies
found significant associations between genetic variants and the
clozapine response (Shaikh et al., 1996; Scharfetter et al., 1999;
Hwang et al., 2010). Shaikh and colleagues investigated an
association between Ser-9-Gly polymorphism (rs6280) in the
DRD3 gene and clozapine response for at least 3 months of
treatment (N = 79), demonstrating that the genotype Ser-9/Ser-
9 was more frequent in the non-responders than in responders
(Shaikh et al., 1996). Scharfetter and colleagues replicated this
finding in patients treated with clozapine for 6 months (N = 32)
(Scharfetter et al., 1999). However, a recent meta-analysis (total
N = 852) suggests no association between Ser-9-Gly and a
clozapine treatment response (Gressier et al., 2016). Hwang
and colleagues demonstrated an association of better clozapine
response for a minimum of 6 months with the A allele of
Frontiers in Pharmacology | www.frontiersin.org 2 September 2018 | Volume 9 | Article 1049










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Frontiers in Pharmacology | www.frontiersin.org 3 September 2018 | Volume 9 | Article 1049














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Frontiers in Pharmacology | www.frontiersin.org 4 September 2018 | Volume 9 | Article 1049
Numata et al. Clozapine Pharmacogenetic Studies in Schizophrenia
rs2134655 in a Caucasian sample (N = 183) and the T allele
of rs1394016 in an African-American sample (N = 49) (Hwang
et al., 2010). With respect to the DRD4 gene (Shaikh et al.,
1993, 1995; Kerwin et al., 1994; Rao et al., 1994; Rietschel
et al., 1996; Kohn et al., 1997; Kaiser et al., 2000; Zhao et al.,
2005; Hwang et al., 2012; Lee et al., 2012; Rajagopal et al.,
2018), two studies found significant associations between genetic
variants and the clozapine response (Zhao et al., 2005; Hwang
et al., 2012). Zhao and colleagues investigated an association
between the 48 bp variant number tandem repeat (VNTR)
polymorphism in the DRD4 gene and clozapine response for at
least 2 months of treatment after clinical stabilization (N = 81),
demonstrating that the frequencies of 5 allele and 5/5 genotype
were higher among the non-responders than in responders
(N = 81) (Zhao et al., 2005). Hwang and colleagues demonstrated
an association between 120-bp 1-copy allele and intron I (G)n
142/140 bp genotype and poor clozapine responders for 6
months of treatment in an African American sample (N = 49),
and an association between 48 bp repeat polymorphism and
better clozapine response in a Caucasian sample (N = 183)
(Hwang et al., 2012). With respect to the DRD5 gene, there
were no significant associations between genetic variants and
the clozapine response (Hwang et al., 2012). With respect to
the COMT gene (Woodward et al., 2007; Bosia et al., 2015;
Rajagopal et al., 2018), two studies found a significant association
between the COMT Val108/158Met polymorphism (rs4680) and
the clozapine response (Woodward et al., 2007; Bosia et al.,
2015). Woodward and colleagues investigated an association
between this polymorphism and clozapine response for 6 weeks
and 6 months of treatment (N = 86), demonstrating that both
the Met/Met and Val/Met groups showed greater improvement
in attention and verbal fluency domains compared to the
Val/Val group (Woodward et al., 2007). Bosia and colleagues
demonstrated a greater improvement in the Val/Val group
compared to both the Val/Met and Met/Met groups in the
negative symptom response for 8 and 16 weeks of treatment
with clozapine (N = 107) (Bosia et al., 2015). With respect to
the SLC6A3 gene, Xu and colleagues demonstrated that the 71T
allele of rs2975226 (T-71A) in the SLC6A3 gene occurred more
frequently in the responders than in non-responders following at
least 8 weeks of treatment with clozapine (Xu et al., 2010).
Serotonin related genes
Clozapine has a high affinity for the 5-hydroxytryptamine
receptor 2A (HTR2A), the 5-hydroxytryptamine receptor 2C
(HTR2C), the 5-hydroxytryptamine receptor 6 (HTR6), and
the 5-hydroxytryptamine receptor 7 (HTR7) (Meltzer, 1994).
To date, genetic variants in the HTR2A, HTR2C, HTR6,
and HTR7 genes as well as in 5-hydroxytryptamine receptor
1A (HTR1A), 5-hydroxytryptamine receptor 3A (HTR3A), 5-
hydroxytryptamine receptor 3B (HTR3B), 5-hydroxytryptamine
receptor 5A (HTR5A), and solute carrier family 6 member 4
(SLC6A4) genes have been investigated in clozapine response
studies, with positive associations observed in the HTR2A,
HTR2C, HTR6, HTR1A, HTR3A, and SLC6A4 genes.
With respect to the HTR2A gene (Arranz et al., 1995a,
1996, 1998b, 2000b; Masellis et al., 1995, 1998; Nöthen et al.,
1995; Malhotra et al., 1996a; Lin et al., 1999; Schumacher
et al., 2000; Yu et al., 2001; Lee et al., 2012), six studies
found significant associations between genetic variants and the
clozapine response (Arranz et al., 1995a, 1996, 1998b, 2000b;
Masellis et al., 1998; Yu et al., 2001). Arransz and colleagues
investigated an association between the T102C polymorphism
(rs6313) in the HTR2A gene and clozapine response for at least
3 months of treatment following clinical stabilization (N = 149),
demonstrating that homozygosity for the C102 allele was more
frequent in the non-responders than in the responders (Arranz
et al., 1995a). Yu and colleagues demonstrated an association
between the 102C/C genotypes and higher N100 amplitude
following clozapine treatment using event-related potentials to
auditory stimuli (N = 98) (Yu et al., 2001). Consistent with
these findings, a recent meta-analysis (total N = 868) suggests
a significant association between the CC genotype and poor
clozapine treatment response (Gressier et al., 2016). Arransz
and colleagues also investigated an association between the
his452tyr polymorphism (rs6314) in the HTR2A gene and
clozapine response (N = 153), demonstrating that the Tyr452
allele occurred more frequently in the non-responders than in
the responders (Arranz et al., 1996). Masellis and colleagues
replicated this finding in subjects who received clozapine for
a minimum of 6 month (N = 185) (Masellis et al., 1998).
Consistent with these findings, a recent meta-analysis (total
N = 671) suggests a significant association between C allele
or C carriers or CC genotype and better clozapine treatment
response compared to T allele or T carriers or TT genotype
(Gressier et al., 2016). Arranz and colleagues also examined an
association between the G-1438A polymorphism (rs6311) in the
HTR2A gene and clozapine response (N = 274), demonstrating
that homozygosity for the G-1438 allele was more frequent in
the non-responders than the responders (Arranz et al., 1998b).
However, a recent meta-analysis (total N = 547) suggests no
association between the G-1438A polymorphism and clozapine
treatment response (Gressier et al., 2016). With respect to
the HTR2C gene (Sodhi et al., 1995; Malhotra et al., 1996b;
Rietschel et al., 1997; Masellis et al., 1998; Arranz et al.,
2000b; Schumacher et al., 2000), two studies found a significant
association between genetic variants and the clozapine response
(Sodhi et al., 1995; Arranz et al., 2000b). Sodhi and colleagues
investigated an association between the Cys23Ser polymorphism
(rs6318) in the HTR2C gene and clozapine response for at
least 3 months treatment after clinical stabilization (N = 162),
demonstrating that Ser allele carriers were more likely to show
a response to clozapine (Sodhi et al., 1995). However, a recent
meta-analysis suggests no association between the Cys23Ser
polymorphism and clozapine treatment response in a Caucasian
sample (Gressier et al., 2016). With respect to the HTR6 gene
(Yu et al., 1999; Masellis et al., 2001; Lee et al., 2012), one
study found a significant association between a genetic variant
and the clozapine response (Yu et al., 1999). Yu and colleagues
examined the association between the C267T polymorphism in
the HTR6 gene and clozapine response for at least 8 weeks of
treatment (N = 99), demonstrating that the 267T/T genotype
was more frequent in responders than in non-responders (Yu
et al., 1999). With respect to the HTR7 gene, there was not a
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significant association between the pro279leu polymorphism and
the clozapine response (Masellis et al., 2001). With respect to the
HTR1A gene (Masellis et al., 2001; Bosia et al., 2015), one study
found a significant association between a genetic variant and
the clozapine response (Bosia et al., 2015). Bosia and colleagues
examined the association between the −1019C/G (rs6295)
polymorphism in the HTR1A gene and clozapine response
for 8 and 16 weeks of treatment (N = 107), demonstrating
a greater improvement in the G/G group compared to the
C/C group (Bosia et al., 2015). With respect to the HTR3A
gene (Arranz et al., 2000b; Gutiérrez et al., 2002; Souza et al.,
2010; Lee et al., 2012; Rajkumar et al., 2012), two studies
found significant associations between genetic variants and the
clozapine response (Souza et al., 2010; Rajkumar et al., 2012).
Souza and colleagues demonstrated the T allele of rs1062613 in
the HTR3A gene was associated with a good clozapine treatment
response when used for at least 6 months (N = 140) (Souza
et al., 2010). Similarly, Rajkumar and colleagues investigated
an association of rs1062613 and rs2276302 in the HTR3A gene
with the clozapine response, demonstrating that the T allele of
rs106263 and the G allele of rs2276302 were associated with
a good clozapine treatment response when presented with a
stable dose for at least 12 weeks (N = 101) (Rajkumar et al.,
2012). Consistent with these findings, a recent meta-analysis
suggested that there may be an association between the T allele
of rs1062613 and an improved response to clozapine (Gressier
et al., 2016). With respect to the HTR3B and HTR5A genes
(Arranz et al., 2000b; Birkett et al., 2000; Gutiérrez et al., 2002;
Souza et al., 2010), there were no significant associations between
genetic variants and the clozapine response. With respect to
the SLC6A4 gene (Arranz et al., 2000a,b; Schumacher et al.,
2000; Tsai et al., 2000; Kohlrausch et al., 2010), two studies
found significant associations between genetic variants and the
clozapine treatment response (Arranz et al., 2000b; Kohlrausch
et al., 2010). Arranz and colleagues demonstrated a significant
association between the biallelic polymorphism in the promoter
region of the SLC6A4 gene, 5-HTTLPR, and the clozapine
response in a Caucasian sample (N = 200) (Arranz et al., 2000b),
and they found a similar trend in a larger sample (N = 268)
(p = 0.08) (Arranz et al., 2000a). Kohlrausch and colleagues
demonstrated that the short allele of HTTLPR/rs25531 occurred
more frequently in the non-responders than in responders
(Kohlrausch et al., 2010) (N = 116).
Glutamatergic receptors
Accumulating evidence suggests the potential for clozapine to
act on glutamatergic neurotransmission (Heresco-Levy, 2003).
To date, genetic variants in the solute carrier family 1 member 2
(SLC1A2), solute carrier family 6 member 9 (SLC6A9), glutamate
ionotropic receptor AMPA type subunit 1 (GRIA1), glutamate
metabotropic receptor 2 (GRM2), and glutamate decarboxylase
1 (GAD1) genes, glutamate ionotropic receptor NMDA type
subunit 1 (GRIN1), glutamate ionotropic receptor NMDA type
subunit 2A (GRIN2A), glutamate ionotropic receptor NMDA
type subunit 2B (GRIN2B), have all been examined in clozapine
treatment response studies, with no significant associations
observed following correction for multiple testing (Hong et al.,
2001; Hwang et al., 2011; Taylor et al., 2016, 2017).
Gene-Gene Interactions
Several trials have been performed to investigate a gene-gene
interaction between multiple candidate genes and the clinical
response to clozapine. Arranz and colleagues examined an
association between 19 genetic polymorphisms in nine clozapine-
targeted receptor subtypes and a neurotransmitter transporter
and the response to clozapine, demonstrating that the strongest
association was with a combination of six polymorphisms
(HTR2A T102C, HTR2A his452tyr, HTR2C−330-GT/-244-CT,
HTR2C Cys23Ser, SLC6A4 5-HTTLPR, and H2−1018-G/A)
(N = 200) (Arranz et al., 2000b). However, Schumacher et al.
could not replicate this finding (Schumacher et al., 2000). Hwang
and colleagues demonstrated the most straightforward gene-
gene- interaction effect of DRD1 rs686 and DRD3 Ser9Gly on the
clozapine treatment response when taken for a minimum of 6
months in a Caucasian sample (N = 183) (Hwang et al., 2011).
Bosia and colleagues demonstrated an additive effect of COMT
Val158Met and HTR1A−1019 C/G on the clozapine treatment
response when taken for 8 and 16 weeks (N = 107) (Bosia
et al., 2015). Similarly, Rajagopal and colleagues demonstrated
a significant gene-gene- interaction effect of DRD4 120-bp
duplication and COMT Val158Met on the clozapine response
when taken for at least 12 weeks (N = 93) (Rajagopal et al.,
2018). Furthermore, Xu and colleagues conducted multivariate
interaction analysis using 77 SNPs of 25 genes and demonstrated
that the combination of rs6269 in the COMT gene and rs3813929
in theHTR2C gene may work as predictor to improve the clinical
antipsychotic response (risperidone, clozapine, quetiapine, and
chlorpromazine) in a large sample set (N = 995) (Xu et al., 2016).
Non-candidate Gene Approach
To date, the authors are unaware of any genome-wide
association studies (GWAS) of clozapine efficacy that have
been published. Recent pharmacogenetics GWAS suggest genetic
overlap between antipsychotic response and susceptibility to
schizophrenia (Ikeda et al., 2015; Ruderfer et al., 2016), and
two genetic variants, identified by GWAS as schizophrenia
risk loci (Cross-Disorder Group of the Psychiatric Genomics
Consortium., 2013; Schizophrenia Working Group of the
Psychiatric Genomics Consortium., 2014), have shown to be
associated with a significant clinical response to clozapine
(Brandl et al., 2016; Huang et al., 2016). Randl and colleagues
demonstrated a significant association between rs2535629 in the
inter-alpha-trypsin inhibitor heavy chainH3 (ITIH3) gene and an
improvement of negative symptoms after 6 months of clozapine
treatment (N = 105) (Brandl et al., 2016). Additionally, Huang
and colleagues demonstrated a significant association between
rs2514218, located upstream of the DRD2 gene, and clozapine
response for 6 months of treatment (N = 208) (Huang et al.,
2016).
Clozapine-Induced Agranulocytosis
The occurrence of clozapine-induced agranulocytosis (CIA) is
0.8% at 1 year of administration of clozapine with reduced
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incidence after the first 6 months of clozapine treatment (Alvir
et al., 1993). A recent meta-analysis suggests that 3.8% of patients
exposed to clozapine will develop mild neutropenia (with an
absolute neutrophil count of <1,500/µl; Myles et al., 2018).
A number of genetic studies of CIA and clozapine-induced
agranulocytosis/granulocytopenia (CIAG) using samples from
patients with schizophrenia have been conducted (Lieberman
et al., 1990; Claas et al., 1992; Corzo et al., 1995; Yunis et al.,
1995; Theodoropoulou et al., 1997; Turbay et al., 1997; Amar
et al., 1998; Valevski et al., 1998; Meged et al., 1999; Dettling
et al., 2000, 2001a,b, 2007; Lahdelma et al., 2001; Ostrousky
et al., 2003; Mosyagin et al., 2004, 2005; Athanasiou et al.,
2011; Anil Yagcioglu et al., 2016; van der Weide et al., 2017),
many focusing on genetic variants in the genes within the major
histocompatibility complex (MHC) region. Positive candidate
gene studies of CIA and CIAG are shown in Table 2.
Candidate Gene Approach
Human leukocyte antigen (HLA) genes
In patients developing CIA (N = 6) compared with controls
(N = 25), Lieberman and colleagues demonstrated that the
occurrence of HLA-B38 as well as the haplotype of HLA-B38,
DR4, and DQw3, was more frequent (Lieberman et al., 1990).
The same laboratory subsequently analyzed them separately by
Ashkenazi Jewish patients and non-Jewish patients, conforming
their previous finding in the Ashkenazi Jewish samples and
demonstrating a significant association of HLA-B7 and DR2
with CIA in non-Jewish patients (Yunis et al., 1995). They
also demonstrated that the variants in the heat-shock protein
70 (HSP-70) and tumor necrosis factor (TNF) genes were
associated with CIA (Corzo et al., 1995; Turbay et al., 1997).
Additionally, Amar and colleagues demonstrated that HLA-
DQB1∗020 significantly occurred more frequently in subjects
who developed CIAG compared to those who did not develop
those complications (5 CIAG cases vs. 13 controls) (Amar
et al., 1998). Valevski and colleagues replicated the involvement
of HLA-B38 in CIA in Jewish Israeli samples (11 CIA
cases vs. 50 controls) (Valevski et al., 1998). Dettling and
colleagues demonstrated a significant association of HLA-Cw∗7,
DQB∗0502, DRB1∗0101, and DRB3∗0202 with CIA in non-
Jewish Caucasian samples (31 CIA cases vs. 77 controls)
(Dettling et al., 2001b). The same laboratory also demonstrated
a significantly higher frequency of HLA-DRB5∗02 and HLA-
DQB∗0502 in patients who developed CIA (Dettling et al.,
2001a). Later, the same laboratory performed an association
study of CIA by combining the HLA class I and class II
genetic variants, demonstrating that HLA-DRDB5∗0201 and
several haplotypes of the HLA genetic variants were associated
with CIA (Dettling et al., 2007). Furthermore, Lahdelma and
colleagues demonstrated that the HLA-B16 allele occurred more
frequently in patients who developed CIAG (22 CIAG cases vs.
120 healthy controls) (Lahdelma et al., 2001), while Athanasiou
and colleagues demonstrated that the HLA-DQB1 “REC 21G”
occurred more frequently in patients who developed CIA
compared with controls in two independent cohorts (Athanasiou
et al., 2011).
Non-human leukocyte antigen (HLA) genes
Ostrousky and colleagues demonstrated that four
polymorphisms in the dihydronicotinamide riboside quinone
oxidoreductase 2 (NQO2) gene were associated with CIA (18
CIA cases vs. 80 controls) (Ostrousky et al., 2003). Additionally,
Mosyagin and colleagues demonstrated that myeloperoxidase
(MPO)−463AA carriers occurred more frequently in patients
who developed CIA compared with AG and GG-carriers
combined (49 CIA cases vs. 78 controls) (Mosyagin et al.,
2004). Furthermore, Athanasiou and colleagues showed that
DRD1, neurotensin receptor 1 (NTSR1), and β chain of colony-
stimulating factor 2 receptor (CSF2RB) as well as HLA-DQB1
and HLA-C were associated with CIA (33 CIA cases vs. 54
controls) (Athanasiou et al., 2011). Van derWeide and colleagues
demonstrated that NQO2 154AA and ABC1 3435TT occurred
more frequently in patients who developed CIA compared
with controls (31 CIA cases vs. 241 controls) (van der Weide
et al., 2017). They also showed that for patients who developed
neutropenia (N = 38), compared to controls (N = 241), ABCB1
3435TT and homozygosity for glutathione S-transferase theta
1 (GSTT1)null occurred more frequently, but glutathione
S-transferase mu 1 (GSTM1)null occurred less frequently (van
der Weide et al., 2017).
Non-candidate Gene Approach
Tiwari and colleagues conducted exome sequence analysis and
did not find any genetic variants associated with CIA in Finnish
patients after Bonferroni correction (13 CIA cases and 11 cases
with severe neutropenia vs. 26 controls) (Tiwari et al., 2014).
Meanwhile, Goldstein and colleagues conducted GWAS, whole-
exome sequencing, and HLA allele imputation and were able to
show that HLA-B 158T and HLA-DQB1 126Q were associated
with CIAG (Goldstein et al., 2014). Legge and colleagues utilized
GWAS, imputed HLA alleles, exome array, and copy-number
variation analyses in a European population and subsequently
combined the data of Goldstein et al. (2014) and Legge et al.
(2017). In their meta-analysis of GWAS, they demonstrated that
rs149104283, an intronic transcript of SLCO1B3 and SLCO1B7,
was associated with clozapine-induced neutropenia. The authors
of this paper conducted GWAS of CIAG in Japanese samples
(50 CIAG cases vs. 2,905 controls) and identified rs1800625
in the HLA region as the CIAG candidate locus (Saito et al.,
2016). A classical HLA analysis was subsequently conducted,
demonstrating a significant association of HLA-B∗59:01 with
CIAG.However, we failed to replicate the risk SNPs on clozapine-
associated neutropenia previously identified by Legge et al. (2017)
in a Japanese population (Saito et al., 2017).
DISCUSSION
In the present article, we summarize clozapine pharmacogenetic
studies, separated by clinical response and CIA. To date,
pharmacogenetic studies of clozapine in schizophrenia have
been mostly conducted through candidate gene approaches.
Genetic variants in the CYP enzyme family, dopamine, and
serotonin receptor genes have been extensively examined as
pharmacokinetic and pharmacodynamics candidates related to
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clozapine efficacy. Although there is limited evidence, the most
recent meta-analyses indicate that only three SNPs (rs6313 and
rs6314 in the HTR2A gene and rs1062613 in the HT3A gene)
are associated with a significant clozapine response (Gressier
et al., 2016). Genetic variants in the genes within the MHC
region have been extensively examined with respect to CIA.
The results of these candidate studies indicate the HLA variants
are implicated in developing CIA. A comprehensive screening
of genetic variants linked to a significant clinical response to
clozapine and CIA is critical because the selection of candidate
genes is restricted to current knowledge about underlying
biological mechanisms (Adkins et al., 2011). Recently, the field
of clozapine pharmacogenetics has shifted from a candidate gene
approach to a genome-wide approach. A genome-wide approach
has successfully identified novel genes that are associated with
CIA and provided further evidence of the involvement of the
HLA variants in CIA (Goldstein et al., 2014; Saito et al., 2016).
On the other hand, there are no known GWAS looking at the
clinical response to clozapine, although there are several GWAS
looking at the antipsychotic treatment response in patients with
schizophrenia (McClay et al., 2011; Drögemöller et al., 2016;
Ruderfer et al., 2016; Li et al., 2017; Yu et al., 2018). Yu and
colleagues conducted GWAS in a large cohort (n = 3,792)
and detected five loci (CNTNAP5, MEGF10, PCDH7, SLC1A1,
and TNIK) associated with general antipsychotic treatment
response (Yu et al., 2018). Interestingly, these loci did not
include DRD2, although D2 receptor blockade in the brain is
a general pharmacodynamic property of antipsychotics (Mauri
et al., 2014).
Pharmacogenetic testing has the potential to help improve
patient outcome, lower healthcare costs, and increase patient
medication adherence (Gardner et al., 2014). Pharmacogenetic
testing in psychiatry is not yet a standard of practice, however,
its utilization is steadily increasing (Eum et al., 2016; Fabbri
et al., 2018). Several studies have, indeed, assessed the clinical
utility for risk genetic variants of CIA. The sensitivity and
specificity of the HLA-DQB1 6672G.>C polymorphism for CIA
in patients treated with clozapine, identified though candidate
approach, was 21.5 and 98.4%, respectively (Athanasiou et al.,
2011). The sensitivity and specificity of the HLA-B∗59:01 for
CIA, identified by GWAS, was 31.8 and 95.3%, respectively (Saito
et al., 2016) and the sensitivity and specificity of HLA-B 158T
and HLA-DQB1 126Q polymorphisms for CIA, identified by
GWAS and whole-exome sequencing (Goldstein et al., 2014),
was 41 and 85%, respectively (Girardin et al., 2018). Clinical
application guidelines requireHLA allele testing for CIA to have a
sensitivity of∼50% (Girardin et al., 2018), therefore none of these
have reached an acceptable threshold for clinical application.
Conversely, we examined the diagnostic performance of non-
risk allele (alleles except for HLA-B∗59:01) on non-CIA among
CIG patients and demonstrated a moderate, positive predictive
value for detecting non-CIA subjects in the CIG group without
the risk allele, suggesting a potential candidate for re-challenging
with clozapine treatment in a Japanese population (Saito et al.,
2016). Based on this finding, a re-challenging with clozapine
following neutropenia in a patient with a low risk of CIAG (HLA-
B∗52:01/52:01) was successfully conducted (Yamaki et al., 2017).
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The decision regarding clozapine re-challenge or withdrawal
in case of CIAG should be based on careful consideration of
risk factors, which can be facilitated by genetic testing in the
future (Wicinski andWeclewicz, 2018). Further efforts to identify
strong and reproducible genetic variants related to the clinical
response to clozapine and CIA are needed to develop appropriate
pharmacogenetic testing of clozapine.
The major issue of pharmacogenetics studies is inconsistent
findings among studies. The discrepancies between these studies
might be caused by statistical issues (i.e., sample size, multiple
testing) and methodological issues (i.e., study design, phenotype
definition, genetic polymorphism, population stratification)
(Ross et al., 2012). Indeed, each sample size of the clozapine
pharmacogenetic studies was relatively small. Large samples
are needed to have enough statistical power to detect the
effects of genetic variants on clinical outcomes by creating a
clozapine consortium (Saito et al., 2016, 2017) or performing
meta-analyses (Gressier et al., 2016; Legge et al., 2017). A
sample size of more than 900 participants will be needed in
a pharmacogenetic study if a common variant is anticipated
with a large effect (Ross et al., 2012). Additionally, most of the
clozapine pharmacogenetic studies did not adjust for themultiple
statistical comparisons, resulting in type I error. To adjust for
multiple testing, a false discovery rate (FDR) correction will
be useful. Furthermore, selection bias and information bias are
confounding factors in both prospective cohort and case-control
studies (Ross et al., 2012). Clinical responses to clozapine have
been determined by several different evaluation scales, including
the Clinical Global Impressions Improvement (CGI-I) score, the
global assessment scale (GAS), the Brief Psychiatric Rating Scale
(BPRS), and Positive and Negative Symptom Scale (PANSS).
Linkage disequilibrium (LD) varies among ethnic population,
which may affect cross-subpopulation comparisons when causal
SNPs are not directly genotyped but rather captures by proxy
SNPs (Ross et al., 2012). Population stratification occurs when
ethnic subpopulations within the entire study population differ
in terms of genotype frequency and risk of disease (Thomas
and Witte, 2002). In addition, clozapine doses and treatment
length as well as types of antipsychotics preceding clozapine
administration differ among studies. Although the clozapine
treatment length in clinical response studies ranges from 5 weeks
to more than 6 months, Lieberman and colleagues reported that
76% of patients responded to clozapine administered up to 52
weeks and slow clozapine responders experienced 70% of their
total improvement after 12 weeks of treatment with clozapine
(Lieberman et al., 1994). Standardized treatment protocols and
evaluations of clinical outcomes will be needed. Furthermore,
both non-genetic and genetic factors play an important role in
the clinical outcome. For example, age at onset, gender, severity
of the illness, negative symptoms, extrapyramidal side effects,
clozapine concentration, history of catatonia, smoking, hyper-
somnolence, and cognitive deficits have all been associated with
the clozapine treatment response (Perry et al., 1991; Lieberman
et al., 1994; Miller et al., 1994; Umbricht et al., 2002; Semiz et al.,
2007; Rajkumar et al., 2013a). To take these factors in analyses
will be needed.
In conclusion, a number of clozapine pharmacogenetic studies
have been performed based on candidate gene approaches.
However, there is heterogeneity across studies and their results
have been inconsistent. Reproducible genetic variants with large
effect related to the clinical response to clozapine and CIA have
not been detected so far. This field is beginning to shift from
candidate gene approaches to more a comprehensive strategy,
such as GWAS and whole genome sequencing, which will
make it possible not only to identify novel genetic variants
related to clinical outcomes, but also to analyze the effects of
multiple genes on clinical outcomes. Extensive effort is required
to apply pharmacogenetic information in clinical practice for a
personalized medicine strategy of clozapine treatment.
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